Bipartisan congressional lawmakers are stressing the importance of strategically advancing psychedelics reform in a way that mitigates bureaucratic conflict and the influence of outside interests. Even just one misstep could threaten to upend the movement, they say.
At a public forum in Washington, D.C.—hosted by the Psychedelic Medicine Coalition (PMC) and Mission Within Foundation (MWF) last week—Reps. Lou Correa (D-CA), Jack Bergman (R-MI) and Morgan Luttrell (R-TX) spoke about the work ahead to provide access to psychedelics for patients.
Much of the focus centered around the need to give military veterans alternative treatment options for serious mental health conditions such as post-traumatic stress disorder (PTSD). Psychedelics like MDMA and ibogaine could help fill that gap, the legislators said.
Luttrell said a key challenge supporters are up against is the inaccessibility of data from private research institutions that could demonstrate the therapeutic efficacy of psychedelics—something that he argued would likely move the needle for members who are on the fence on the issue.
The congressman said he and colleagues have pressed agencies such as the Department of Defense (DOD), U.S. Department of Veterans Affairs (VA) and U.S. Department of Health and Human Services (HHS) about the problem.
“How do you get
Read full article on Marijuana Moment
